On 20th April Nic Puntis (Chair GSUK) & Jayne Bressington (Vice Chair GSUK / Patient Director PAWS-GIST, pictured left) went to Westminster and attended a parliamentary reception organised by Cancer52, a coalition of more than 80 charities representing rare and less common cancers. The reception was hosted and addressed by Chairman of the All-Party Parliamentary Group on Cancer […]

In 2012 GIST Support UK granted £20,000 funding to Professor Ian Judson and his team at the Royal Marsden for a research project. This project aimed to collect tissue samples stored in hospital pathology departments for GIST patients who had been treated at the Marsden over previous years and then to retrospectively undertake mutational analysis of […]

We still have one place available. Go to our Fundraising page for more details.

As you may already be aware, great news was released on Friday 4th September that Regorafenib has remained on the NHS England Cancer Drug Fund List for GIST patients, having stayed above the threshold for inclusion on the CDF, further to the second phase of review. At the patient organisation briefing in Whitehall this morning, […]

Click here to read about the latest clinic news…

We are delighted to report that Regorafenib has been recommended for use within NHS Wales for GIST Please see the AWMSG Website. This means that within three months of Ministerial approval (issued July 2015), regorafenib will be routinely available in the NHS across Wales. A fantastic outcome for GIST patients in Wales!

Sincere thanks to everyone who has supported us with the call to retain regorafenib on the Cancer Drugs fund for GIST patients. Yesterday was our appointment with No. 10 Downing Street to deliver our #100,000voices e-petition containing 103,841 signatures supporting retention of regorafenib for GIST patients in England. We were joined by MP’s representing constituents […]

regorafenib has been approved in Scotland for treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who have progressed on or are intolerant to prior treatment with imatinib and sunitinib. This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of regorafenib and is contingent […]

March 2015 Jayne Bressington, vice chair of GIST Support UK (https://www.gistcancer.org.uk/), talks to BBC Radio Humberside about the government’s plans to stop funding for the rare cancer drug Regorafenib. The petition to stop these cuts has gained 100,000+ signatures and we are now calling on everyone to write to their local parliamentary candidates ahead of […]